Theravance Biopharma is now part of Zymeworks. Follow @ZymeworksInc for updates.
Joined July 2020
- Tweets196
- Following117
- Followers392
- Likes41
Pinned Tweet
Theravance Biopharma is now part of @Zymeworks. We’re excited to join the Zymeworks team and look forward to what’s ahead. Read the announcement: bit.ly/3V9L47L
We celebrate our CEO Rick Winningham for being named @HBAnet’s 2026 Honorable Mentor. Over decades of leadership, he has championed leaders & shaped a robust talent pipeline that nurtures the next generation of #healthcare trailblazers. Read more: bit.ly/4aZ0EsW
Theravance Biopharma retweeted
Join @TheravanceBio $TBPH on Dec. 8 at 10:30am ET for a virtual KOL investor event with Dr. Kaufmann, who will join company management to discuss the unmet medical need for symptomatic nOH in patients with MSA.
Register: bit.ly/4reZGOK
Today, we announced our Q3 2025 Financial Results and Business Update. Join us at 2 PM PT/5 PM ET: tinyurl.com/574hesvu $TBPH
Are you at #AAS2025? Find us at:
Poster Session II | Nov 6 | 7:00–8:30PM EST
Platform Presentation | Nov 8 | 8:30–8:45AM EST
#MovementDisorders
Explore nOH due to MSA with us at the American Autonomic Society's 36th International Symposium on the Autonomic Nervous System. Find us in the Exhibit Hall. Discover more at nOHUncovered.com
Power. Periphery. Potential.
See how it all connects in nOH associated with MSA at
#MDSCongress with Theravance Biopharma.
Discover more at nohuncovered.com #movementdisorders
In nOH due to MSA, preserved peripheral neurons may play a bigger role than you think—and we’re diving into the science. Stop by Booth 339 at #MDSCongress to learn more. #movementdisorders
In nOH due to MSA, preserved peripheral neurons may play a bigger role than you think—and we’re diving into the science. Stop by Booth 339 at #MDSCongress to learn more. #movementdisorders
Proud to sponsor #EFAS2025 in Toulouse this September. We look forward to connecting with researchers, clinicians, and peers in the autonomic disorders community.
Learn more about EFAS 2025: efas2025.com/
Theravance Biopharma is proud to partner with Defeat MSA Alliance as a sponsor of the 6th Free All-Community Virtual MSA Conference. Join us and be part of this important community event. Register here: tinyurl.com/4syf5z48
CEO Rick Winningham will be participating in a fireside chat today at the @HCWCO 27th Annual Global Investment Conference in New York City at 1:30 PM EDT/10:30 AM PDT. To join the webcast, click here: tinyurl.com/46v9fh6m $TBPH #HCWConference
Today, we announced enrollment is complete in our pivotal Phase 3 CYPRESS study of ampreloxetine in patients with symptomatic nOH due to multiple system atrophy, with top-line results anticipated in Q1 2026. To learn more: tinyurl.com/ur747vb7 $TBPH
@TheravanceBio is currently recruiting for the Phase 3 CYPRESS #clinicaltrial evaluating the efficacy & safety of a once-daily investigational drug with the goal of symptom relief in people with nOH & #multiplesystematrophy. Learn more on qualifying: cypress-study.com
We are researching an investigational drug aiming to reduce nOH symptoms in MSA patients. Symptoms of nOH can impact the ability to conduct daily activities, especially those requiring standing or walking. Learn more about the Phase 3 CYPRESS study here: cypress-study.com
Today we celebrate #ClinicalTrialsDay!
Thank you to the researchers, participants, and caregivers who make clinical progress possible. Your dedication drives innovation and hope. #ClinicalTrialsDay #CTD2025 @ACRPDC
Grateful to have attended, participated in, and sponsored the International MSA Congress in Boston, hosted by @MissionMSA. Inspiring days full of learning, connection, and commitment to the MSA community. Thank you to all who made it happen! #MSA2025
Spring into action this May! Symptomatic nOH affects approximately 70-90% of those with MSA. If you/someone you know diagnosed with MSA experience symptoms of nOH, you may quality to participate in our actively recruiting Phase 3 CYPRESS Study. Learn more: cypress-study.com
Analyses of the initial Phase 3 Program of ampreloxetine (Studies 0169 & 0170) will be presented today at 9:40 AM ET in an oral presentation at the @MissionMSA International MSA Congress in Boston. Poster sessions: May 9–10. #MSA2025 Program details missionmsa.org/intlmsacongre…
